La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Heidelberg Pharma Résultats passés
Passé contrôle des critères 0/6
Heidelberg Pharma's earnings have been declining at an average annual rate of -9.3%, while the Biotechs industry saw earnings growing at 11.8% annually. Revenues have been growing at an average rate of 14% per year.
Informations clés
-9.3%
Taux de croissance des bénéfices
0.3%
Taux de croissance du BPA
Biotechs Croissance de l'industrie | -14.6% |
Taux de croissance des recettes | 14.0% |
Rendement des fonds propres | -31.7% |
Marge nette | -137.2% |
Dernière mise à jour des bénéfices | 31 May 2024 |
Mises à jour récentes des performances passées
Recent updates
Is Heidelberg Pharma (ETR:HPHA) A Risky Investment?
Feb 16Heidelberg Pharma AG's (ETR:HPHA) Price In Tune With Revenues
Dec 05Industry Analysts Just Upgraded Their Heidelberg Pharma AG (ETR:HPHA) Revenue Forecasts By 21%
Jul 21Analyst Forecasts For Heidelberg Pharma AG (ETR:HPHA) Are Surging Higher
Oct 16Heidelberg Pharma (ETR:HPHA) Will Have To Spend Its Cash Wisely
Nov 28Heidelberg Pharma AG (ETR:HPHA) Analysts Are More Bearish Than They Used To Be
Mar 27We Think Heidelberg Pharma (ETR:HPHA) Needs To Drive Business Growth Carefully
Mar 15Investors Who Bought Heidelberg Pharma (ETR:HPHA) Shares Five Years Ago Are Now Up 245%
Jan 17We Think Heidelberg Pharma (ETR:HPHA) Needs To Drive Business Growth Carefully
Dec 14Ventilation des recettes et des dépenses
Comment Heidelberg Pharma gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
---|---|---|---|---|
31 May 24 | 10 | -13 | 7 | 24 |
29 Feb 24 | 9 | -18 | 6 | 27 |
30 Nov 23 | 10 | -20 | 6 | 28 |
31 Aug 23 | 10 | -22 | 6 | 31 |
31 May 23 | 11 | -27 | 5 | 29 |
28 Feb 23 | 20 | -19 | 6 | 26 |
30 Nov 22 | 19 | -20 | 6 | 26 |
31 Aug 22 | 17 | -21 | 6 | 22 |
31 May 22 | 13 | -22 | 6 | 20 |
28 Feb 22 | 2 | -27 | 5 | 20 |
30 Nov 21 | 2 | -26 | 4 | 19 |
31 Aug 21 | 2 | -25 | 4 | 19 |
31 May 21 | 7 | -22 | 4 | 20 |
28 Feb 21 | 7 | -20 | 4 | 19 |
30 Nov 20 | 9 | -18 | 4 | 18 |
31 Aug 20 | 10 | -17 | 4 | 17 |
31 May 20 | 7 | -15 | 4 | 15 |
29 Feb 20 | 8 | -12 | 4 | 12 |
30 Nov 19 | 7 | -10 | 3 | 11 |
31 Aug 19 | 7 | -10 | 3 | 11 |
31 May 19 | 6 | -11 | 3 | 11 |
28 Feb 19 | 4 | -12 | 3 | 12 |
30 Nov 18 | 4 | -12 | 3 | 11 |
31 Aug 18 | 4 | -11 | 3 | 10 |
31 May 18 | 3 | -11 | 3 | 10 |
28 Feb 18 | 2 | -11 | 3 | 10 |
30 Nov 17 | 2 | -11 | 3 | 9 |
31 Aug 17 | 2 | -10 | 3 | 8 |
31 May 17 | 2 | -8 | 2 | 7 |
28 Feb 17 | 2 | -7 | 2 | 6 |
30 Nov 16 | 2 | -6 | 2 | 6 |
31 Aug 16 | 2 | -7 | 4 | 6 |
31 May 16 | 2 | -7 | 4 | 5 |
29 Feb 16 | 2 | -7 | 5 | 5 |
30 Nov 15 | 3 | -7 | 5 | 4 |
31 Aug 15 | 3 | -5 | 3 | 5 |
31 May 15 | 5 | -3 | 3 | 4 |
28 Feb 15 | 4 | -4 | 3 | 4 |
30 Nov 14 | 4 | -6 | 4 | 6 |
31 Aug 14 | 7 | -5 | 6 | 9 |
31 May 14 | 9 | -6 | 7 | 10 |
28 Feb 14 | 11 | -6 | 7 | 11 |
30 Nov 13 | 14 | -5 | 8 | 12 |
31 Aug 13 | 16 | -6 | 4 | 10 |
Des revenus de qualité: HPHA is currently unprofitable.
Augmentation de la marge bénéficiaire: HPHA is currently unprofitable.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: HPHA is unprofitable, and losses have increased over the past 5 years at a rate of 9.3% per year.
Accélération de la croissance: Unable to compare HPHA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Bénéfices par rapport au secteur d'activité: HPHA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-0.08%).
Rendement des fonds propres
ROE élevé: HPHA has a negative Return on Equity (-31.73%), as it is currently unprofitable.